PROJECT STAGE
Lead optimisation
Hit to lead
Screening
Assay Development
Therapeutic area
  • Cancer

Project Aim

To identify potent ULK1 inhibitors of the mTOR induced autophagy pathway

Advantage

Blocking ULK1, as the main arbiter of autophagy, will result in enhanced tumour cell death in combination with chemo and radiotherapy

Target Class

Enzyme (kinase)

Modality

Small molecule

Current Status

Hit to Lead with preliminary in-vivo data

Intellectual Property

Opportunity to create a protective IPR portfolio

Offering

Licence or shared risk collaboration

Key Contact

  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email support@thewebkitchen.co.uk.
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
  • We would love to send you information about LifeArc news and events. Please let us know if you would like us to contact you by selecting one of the following options:
All Licensing Opportunities